Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14068013 | 1.00 | SIGMAR1 (0.47) | SIGMAR1ADORA2AHSD11B1PARP1RAB9A | |
| SCHEMBL14068055 | 1.00 | SIGMAR1 (0.47) | SIGMAR1ADORA2AHSD11B1PARP1RAB9A | |
| SCHEMBL703644 | 0.84 | HSD11B1 (0.46) | SIGMAR1HSD11B1 | |
| SCHEMBL703645 | 0.84 | HSD11B1 (0.46) | SIGMAR1HSD11B1 | |
| SCHEMBL18779976 | 0.73 | SIGMAR1 (0.57) | SIGMAR1ADORA2APARP1RAB9AALDH1A1 | |
| SCHEMBL18779975 | 0.73 | SIGMAR1 (0.57) | SIGMAR1ADORA2APARP1RAB9AALDH1A1 | |
| SCHEMBL14068042 | 0.72 | NOTUM (0.43) | SIGMAR1HSD11B1EPHX2HTR2CHTR2B | |
| SCHEMBL29802801 | 0.72 | KMT2A (0.49) | HSD11B1RAB9AALDH1A1EPHX2HTR2A | |
| SCHEMBL20507420 | 0.72 | KMT2A (0.49) | HSD11B1RAB9AALDH1A1EPHX2HTR2A | |
| SCHEMBL3835666 | 0.71 | HSD11B1 (0.43) | SIGMAR1ADORA2AHSD11B1EPHX2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563591-B2 | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-10-22 | — | — | US | claimed |
| EP-1786774-B1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-14 | — | — | EP | claimed |
| US-20080214597-A1 | 2-Adamantan-2-yl-2,3,3a,4,9,9a-hexahydro-benzo[f]isoindol-1-one; obesity, diabetes, obesity related cardiovascular diseases, dementia, cognition, osteoporosis, stress and glaucoma | JANSSEN PHARMACEUTICAL N.V. (BE) | 2008-09-04 | — | — | US | claimed |
| EP-1786774-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-23 | — | — | EP | claimed |
| WO-2006024628-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-09 | — | — | WO | claimed |
| US-10894054-B2 | FXR agonist compositions for combination therapy | INTERCEPT PHARMACEUTICALS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-20180117065-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS, INC. | 2018-05-03 | — | — | US | disclosed |
| US-20180117065-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS, INC. | 2018-05-03 | — | — | US | disclosed |
| US-9630921-B2 | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-25 | — | — | US | disclosed |
| US-20160318865-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | US | disclosed |
| WO-2016164413-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS, INC. (US) | 2016-10-13 | — | — | WO | disclosed |
| US-9422284-B2 | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-08-23 | — | — | US | disclosed |
| US-20160002229-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-07 | — | — | US | disclosed |
| US-9150512-B2 | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-10-06 | — | — | US | disclosed |
| US-20140179732-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-26 | — | — | US | disclosed |
| US-8563591-B2 | Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-10-22 | — | — | US | disclosed |
| EP-1786774-B1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-14 | — | — | EP | disclosed |
| US-20080214597-A1 | 2-Adamantan-2-yl-2,3,3a,4,9,9a-hexahydro-benzo[f]isoindol-1-one; obesity, diabetes, obesity related cardiovascular diseases, dementia, cognition, osteoporosis, stress and glaucoma | JANSSEN PHARMACEUTICAL N.V. (BE) | 2008-09-04 | — | — | US | disclosed |
| EP-1786774-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024628-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002229-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | HSD17B1, HSD17B11, HSD11B1 | SIGMAR1 2693/4885ADORA2A 4754/4885HSD11B1 3/4885 |
| US-10894054-B2 | FXR agonist compositions for combination therapy | GPR119, FXR1, NR1H4 | SIGMAR1 1969/4885ADORA2A 568/4885HSD11B1 241/4885 |
| US-20080214597-A1 | 2-Adamantan-2-yl-2,3,3a,4,9,9a-hexahydro-benzo[f]isoindol-1-one; obesity, diabetes, obesity related cardiovascular diseases, dementia, cognition, osteoporosis, stress and glaucoma | CHRM1, CHRNA7, CHRM5 | SIGMAR1 191/4885ADORA2A 2235/4885HSD11B1 136/4885 |
| US-20180117065-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | GPR119, FABP1, SLC10A1 | SIGMAR1 2275/4885ADORA2A 697/4885HSD11B1 214/4885 |
| US-20160318865-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | HSD17B1, HSD17B11, HSD11B1 | SIGMAR1 2693/4885ADORA2A 4754/4885HSD11B1 3/4885 |
| US-20140179732-A1 | TRICYCLIC LACTAM DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | HSD17B1, HSD17B11, HSD11B1 | SIGMAR1 2693/4885ADORA2A 4754/4885HSD11B1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.